News

Dosing begins in gene therapy trial for DMD-linked heart disease

The first patient has been dosed as part of a Phase 1b clinical trial of AAV1.SERCA2 (SRD-003), Sardocor‘s one-time gene therapy for cardiomyopathy — a type of heart disease — associated with Duchenne muscular dystrophy (DMD-CM). The multicenter trial, dubbed MUSIC-DMD (NCT06224660), is being conducted in collaboration…

Capricor plans for deramiocel resubmission after FDA rejection

Capricor Therapeutics will resubmit its application for U.S. Food and Drug Administration (FDA) approval of its cell therapy deramiocel to treat Duchenne muscular dystrophy (DMD)-related heart disease, following the agency’s decision to not accept the original filing. According to a company press release, the FDA issued a…

Households caring for DMD patients face high costs: US survey

Households incur substantial costs to accommodate people with Duchenne muscular dystrophy (DMD), according to a survey of patient caregivers in the U.S. Costs, such as those for purchasing and/or modifying an accessible vehicle, relocating to or building an accessible home, modifying home entrances, and buying medical equipment, were particularly…

Disease progression reflected by blood protein signature: Study

Researchers identified a unique protein signature in the bloodstreams of adults with Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD) that significantly differs from healthy individuals after exercise. “We propose that a subset of circulating proteins may be more indicative of disease progression and/or therapeutic efficacy than…

Duvyzat conditionally approved by EC to treat Duchenne MD

The European Comission has conditionally approved Duvyzat (givinostat) to be taken alongside corticosteroids for treating people who are 6 and older with Duchenne muscular dystrophy (DMD). “This milestone means that a broad range of patients with DMD have access to a new treatment,” Francesco De Santis, president of…